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Clinical PerspectiveWhat Is New?Observational data are lacking about the relation between diabetes mellitus, glycemic control, and ischemic and bleeding events in patients with stable coronary artery disease receiving modern secondary prevention.We demonstrated that the 5‐year increased risk of ischemic events in diabetic patients with coronary artery disease was restricted to those with glycosylated hemoglobin ≥7%.By contrast, the increase in bleeding risk associated with diabetes mellitus was observed in patients with glycosylated hemoglobin ≥7% and in patients with glycosylated hemoglobin \<7%.What Are the Clinical Implications?Our data suggest that the level of glycosylated hemoglobin should be taken into account for future research and intervention trials in diabetic patients with coronary artery disease.Our results may help physicians to manage prolonged antithrombotic therapies in diabetic patients with stable coronary artery disease.

Introduction {#jah33186-sec-0008}
============

Diabetic patients with short‐ or long‐term manifestations of coronary artery disease (CAD) have been shown to be at higher risk of ischemic cardiovascular events than nondiabetic patients.[1](#jah33186-bib-0001){ref-type="ref"}, [2](#jah33186-bib-0002){ref-type="ref"}, [3](#jah33186-bib-0003){ref-type="ref"} In addition, it has been demonstrated that the cardiovascular prognosis of diabetic patients with CAD undergoing percutaneous coronary intervention is worse when the level of glycosylated hemoglobin (HbA1c) is high.[4](#jah33186-bib-0004){ref-type="ref"}, [5](#jah33186-bib-0005){ref-type="ref"} However, in a context of major improvement in secondary prevention,[6](#jah33186-bib-0006){ref-type="ref"}, [7](#jah33186-bib-0007){ref-type="ref"}, [8](#jah33186-bib-0008){ref-type="ref"}, [9](#jah33186-bib-0009){ref-type="ref"} there is a lack of recent studies evaluating these issues in patients with stable CAD who are known to be at relatively low cardiovascular risk overall.[10](#jah33186-bib-0010){ref-type="ref"}, [11](#jah33186-bib-0011){ref-type="ref"} In addition, although patients with CAD with diabetes mellitus (DM) have also been shown to be at higher risk of bleeding,[12](#jah33186-bib-0012){ref-type="ref"}, [13](#jah33186-bib-0013){ref-type="ref"}, [14](#jah33186-bib-0014){ref-type="ref"} an event with important prognostic consequences,[14](#jah33186-bib-0014){ref-type="ref"}, [15](#jah33186-bib-0015){ref-type="ref"}, [16](#jah33186-bib-0016){ref-type="ref"} whether this risk may vary according to DM control (HbA1c level) has not been established. Updated knowledge on these issues could be useful because it may allow to better understand the benefit/risk ratio of antithrombotic therapies in patients with CAD who also have DM.

We, thus, designed the present analysis to describe secondary medical prevention, risk factors, and 5‐year clinical ischemic and bleeding outcomes according to diabetic status in 4184 outpatients with stable CAD included in the CORONOR (Suivi d\'une cohorte de patients Coronariens stables en région Nord‐pas‐de‐Calais) registry. We also explored the potential refinement to risk stratification that may spring from subdividing DM according to the level of HbA1c.

Methods {#jah33186-sec-0009}
=======

This cohort study used prospectively collected data from the CORONOR registry. The study was approved by the French medical data protection committee and authorized by the Commission Nationale de l\'Informatique et des Libertés for the treatment of personal health data. All patients consented to the study after being informed through a written document of the objectives of the study and on the treatment of data, as well as on their rights to object, of access and of rectification. Because of data protection principles, the data will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Study Population {#jah33186-sec-0010}
----------------

The CORONOR registry is a prospective multicenter registry that included 4184 consecutive outpatients with stable CAD. The study population has been previously described in detail.[11](#jah33186-bib-0011){ref-type="ref"} The patients were included by 50 cardiologists from the region Nord Pas‐de‐Calais in France between February 1, 2010 and April 30, 2011. The inclusion criterion was evidence of CAD, defined by at least 1 of the following: previous myocardial infarction (MI) (\>1 year ago), previous coronary revascularization (\>1 year ago), and/or obstruction of ≥50% of the luminal diameter of at least 1 native coronary vessel on coronary angiography. The sole exclusion criterion was hospitalization for MI or coronary revascularization within the past year.

Study Design and Definitions {#jah33186-sec-0011}
----------------------------

A case record form, which contained information about demographic and clinical details of the patients, including usual cardiovascular risk factors and treatments, was prospectively completed at initial visit by the investigators (ie, the cardiologist). DM was defined as a patient treated with oral hypoglycemic drugs or insulin or with a history of elevated (\>126 mg/dL) fasting blood glucose on at least 2 separate occasions in conjunction with ongoing dietary measures. In case of DM, the most recent HbA1c value (within 12 months before the inclusion visit) was entered in the case record form. History of hypertension was defined as a patient receiving ≥1 antihypertensive treatment. Prior MI included ST‐segment--elevation MI and non--ST‐segment--elevation MI. Multivessel CAD was defined as ≥2 coronary arteries with ≥50% stenosis. Left ventricular ejection fraction was the most recent echocardiographic assessment. Estimated glomerular filtration rate was obtained by the MDRD (Modification of Diet in Renal Disease) Study equation.

Clinical follow‐up was performed at outpatient visits with treating cardiologists using a standardized case record form to report clinical events.[17](#jah33186-bib-0017){ref-type="ref"} The number of outpatient visits was at the discretion of the treating cardiologists. Protocol‐specified follow‐up was performed at 2 and at 5 years. When a clinical event was reported, all related documents (reports of outpatient visits and discharge summaries) were collected. Missing information was completed by contacting either general practitioners and/or patients themselves. We collected follow‐up data on death, MI, ischemic stroke, and major bleeding. Four investigators participated to the adjudication process (T.M., O.T., N.L., C.B.). All clinical events were adjudicated by 2 investigators blinded to each other. A third investigator joined the adjudication in case of disagreement according to prespecified definitions. For hospitalizations during the follow‐up period, hospital records were reviewed for evidence of clinical events. The events reported by the patients were systematically confirmed from the medical reports. The cause of death was determined after a detailed review of the circumstances of death and classified as cardiovascular or noncardiovascular.[18](#jah33186-bib-0018){ref-type="ref"} Deaths from unknown cause were considered as cardiovascular (we also performed a sensitivity analysis after considering unknown deaths as noncardiovascular for the present analysis). MI was defined according to the universal definition.[17](#jah33186-bib-0017){ref-type="ref"}, [19](#jah33186-bib-0019){ref-type="ref"} Ischemic stroke was defined as a sudden onset of focal neurological symptoms with the presence of cerebral infarction in the appropriate territory on brain imaging. To assess ischemic risk, a composite end point was defined as cardiovascular death, MI, or ischemic stroke. Bleeding events were classified using the Bleeding Academic Research Consortium definition.[20](#jah33186-bib-0020){ref-type="ref"} Information on Bleeding Academic Research Consortium type 1 and 2 bleeds was not available in our registry. Major bleeding was defined as all Bleeding Academic Research Consortium type ≥3 events.

For the present analysis, we compared 3 groups of patients: nondiabetic patients, diabetic patients with an HbA1c at inclusion \<7%, and diabetic patients with an HbA1c at inclusion ≥7%. The choice of the cutoff of 7% was based on recommendations for glycemic control in stable patients with CAD with DM, as summarized by international guidelines.[7](#jah33186-bib-0007){ref-type="ref"}

Statistical Analysis {#jah33186-sec-0012}
--------------------

Continuous variables were described as the mean±SD. Categorical variables were presented as absolute numbers and percentages. For comparisons among the 3 patients groups of baseline characteristics, treatments, and risk factor control, we used the χ^2^ test for categorical variables and ANOVA for continuous variables. Post hoc comparisons between groups were performed with Bonferroni corrections. Cumulative rates of events were estimated for nondiabetic patients, diabetic patients with an HbA1c at inclusion \<7%, and diabetic patients with an HbA1c at inclusion ≥7% using the Kaplan‐Meier method, and the difference was tested with the log‐rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated by the Cox model, with nondiabetic patients as the reference group. The proportional hazard assumption was assessed and satisfied by Schoenfeld residuals and by including an interaction time‐dependent term in the Cox regression analysis. HRs were first assessed unadjusted and then adjusted for baseline characteristics. We performed 2 sensitivity analyses: first, after reclassifying unknown deaths as noncardiovascular; and second, assessing separately all‐cause death and the nondeath composite of MI or ischemic stroke. In this second sensitivity analysis, the association with the nondeath composite was performed using competitive risk regression, with death as the competing event, according to the method of Fine and Gray[21](#jah33186-bib-0021){ref-type="ref"}; sub‐HRs (SHRs) and 95% CIs were calculated. All statistical analyses were performed with the STATA 14.0 software (STATA Corporation, College Station, TX). Statistical significance was assumed at *P*\<0.05.

Results {#jah33186-sec-0013}
=======

Population {#jah33186-sec-0014}
----------

The baseline characteristics of the 4184 patients included in the CORONOR registry have been previously reported.[11](#jah33186-bib-0011){ref-type="ref"} This was a predominantly male cohort (78%), with a mean age of 67±12 years. A history of MI was documented in 62% of the cases, with 86% of the patients having had at least 1 prior coronary revascularization procedure. The cohort overall received a broad range of secondary prevention drugs (antiplatelets in 96%, inhibitors of the renin‐angiotensin system in 82%, and statins in 92%). At inclusion into the registry, there were 2887 nondiabetic patients (69%) and 1297 diabetic patients (31%). In the diabetic subgroup, a recent HbA1c measurement was available for 1146 patients: 594 patients (52%) had an HbA1c \<7%, whereas 552 patients (48%) had an HbA1c ≥7%; 151 patients had no recent HbA1c measurement available.

Comparisons in baseline characteristics, medications at inclusion, and risk factor control at inclusion among nondiabetic patients, diabetic patients with HbA1c \<7%, and diabetic patients with HbA1c ≥7% are shown in Tables [1](#jah33186-tbl-0001){ref-type="table"}, [2](#jah33186-tbl-0002){ref-type="table"} through [3](#jah33186-tbl-0003){ref-type="table"}, respectively. When compared with diabetic patients with HbA1c \<7%, diabetic patients with HbA1c ≥7% had slightly lower left ventricular ejection fraction, were more often female, and were more likely to have persistent angina, multivessel CAD, and prior drug‐eluting coronary stent implantation. The prescription rate of cardiovascular treatments in diabetic patients did not differ according to HbA1c levels. There were, by contrast, differences in antidiabetic medications with, in particular, a much higher use of insulin in the subgroup with an HbA1c ≥7%. Except for a slightly higher proportion of current smokers and for a higher body mass index in case of HbA1c ≥7%, risk factor control in diabetic patients did not differ according to HbA1c levels.

###### 

Baseline Characteristics of the Study Population, According to Diabetic Status and DM Control

  Characteristics                           Nondiabetic Patients (n=2887)   Diabetic Patients With HbA1c \<7% (n=594)          Diabetic Patients With HbA1c ≥7% (n=552)
  ----------------------------------------- ------------------------------- -------------------------------------------------- ----------------------------------------------------------------------------------------------
  Age, y                                    67±12                           67±9                                               67±10
  Women                                     622 (22)                        115 (19)                                           156 (28)[\*](#jah33186-note-0003){ref-type="fn"} ^,^ [†](#jah33186-note-0003){ref-type="fn"}
  Persistent angina at inclusion            185 (6)                         38 (6)                                             68 (12)[\*](#jah33186-note-0003){ref-type="fn"} ^,^ [†](#jah33186-note-0003){ref-type="fn"}
  History of hypertension                   1530 (53)                       451 (76)[\*](#jah33186-note-0003){ref-type="fn"}   421 (76)[\*](#jah33186-note-0003){ref-type="fn"}
  Prior MI                                  1853 (64)                       346 (58)[\*](#jah33186-note-0003){ref-type="fn"}   330 (60)
  Prior coronary angiography                2864 (99)                       587 (99)                                           547 (99)
  Multivessel CAD                           1574 (55)                       355 (60)                                           373 (68)[\*](#jah33186-note-0003){ref-type="fn"} ^,^ [†](#jah33186-note-0003){ref-type="fn"}
  Prior coronary revascularization          2511 (87)                       497 (84)                                           459 (83)[\*](#jah33186-note-0003){ref-type="fn"}
  Prior BMS implantation                    1608 (56)                       288 (48)[\*](#jah33186-note-0003){ref-type="fn"}   251 (45)[\*](#jah33186-note-0003){ref-type="fn"}
  Prior DES implantation                    654 (23)                        159 (27)                                           193 (35)[\*](#jah33186-note-0003){ref-type="fn"} ^,^ [†](#jah33186-note-0003){ref-type="fn"}
  Prior coronary bypass                     602 (21)                        134 (23)                                           122 (22)
  Prior stroke                              188 (7)                         63 (11)[\*](#jah33186-note-0003){ref-type="fn"}    53 (10)[\*](#jah33186-note-0003){ref-type="fn"}
  Prior carotid endarterectomy              72 (2)                          26 (4)[\*](#jah33186-note-0003){ref-type="fn"}     20 (4)
  Prior aortic or peripheral intervention   254 (9)                         65 (11)                                            52 (9)
  Atrial fibrillation                       195 (7)                         43 (7)                                             50 (9)
  LVEF, %                                   58±11                           57±11                                              55±12[\*](#jah33186-note-0003){ref-type="fn"} ^,^ [†](#jah33186-note-0003){ref-type="fn"}
  Estimated GFR, mL/min per 1.73 m^2^       80±23                           78±25                                              74±27[\*](#jah33186-note-0003){ref-type="fn"}

Data are given as mean±SD or number (percentage). BMS indicates bare metal coronary stent; CAD, coronary artery disease; DES, drug‐eluting coronary stent; DM, diabetes mellitus; GFR, glomerular filtration rate by the MDRD (Modification of Diet in Renal Disease) Study equation; HbA1c, glycosylated hemoglobin; LVEF, left ventricular ejection fraction; MI, myocardial infarction.

\**P*\<0.05 vs nondiabetic patients; ^†^ *P*\<0.05 vs diabetic patients with HbA1c \<7%.

###### 

Baseline Medications at Inclusion, According to Diabetic Status and DM Control

  Medications                     Nondiabetic Patients (n=2887)   Diabetic Patients With HbA1c \<7% (n=594)          Diabetic Patients With HbA1c ≥7% (n=552)
  ------------------------------- ------------------------------- -------------------------------------------------- --------------------------------------------------
  Aspirin                         2236 (77)                       444 (75)                                           420 (76)
  Clopidogrel                     1109 (38)                       258 (43)                                           253 (46)[\*](#jah33186-note-0005){ref-type="fn"}
  Aspirin or clopidogrel          2775 (96)                       572 (96)                                           537 (97)
  Aspirin and clopidogrel         570 (20)                        130 (22)                                           136 (25)[\*](#jah33186-note-0005){ref-type="fn"}
  Vitamin K antagonists           309 (11)                        65 (11)                                            75 (14)
  ACE inhibitors                  1710 (59)                       346 (58)                                           331 (60)
  ARBs                            606 (21)                        187 (31)[\*](#jah33186-note-0005){ref-type="fn"}   179 (32)[\*](#jah33186-note-0005){ref-type="fn"}
  ACE inhibitors or ARBs          2288 (79)                       518 (87)[\*](#jah33186-note-0005){ref-type="fn"}   492 (89)[\*](#jah33186-note-0005){ref-type="fn"}
  Aldosterone antagonists         175 (6)                         46 (8)                                             49 (9)[\*](#jah33186-note-0005){ref-type="fn"}
  ß Blockers                      2243 (78)                       488 (82)[\*](#jah33186-note-0005){ref-type="fn"}   465 (84)[\*](#jah33186-note-0005){ref-type="fn"}
  Statins                         2679 (93)                       542 (91)                                           496 (90)
  Calcium antagonists             664 (23)                        174 (29)[\*](#jah33186-note-0005){ref-type="fn"}   171 (31)[\*](#jah33186-note-0005){ref-type="fn"}
  Diuretics                       743 (26)                        251 (42)[\*](#jah33186-note-0005){ref-type="fn"}   263 (48)[\*](#jah33186-note-0005){ref-type="fn"}
  Insulin                         ···                             85 (14)                                            233 (42)[†](#jah33186-note-0005){ref-type="fn"}
  Biguanides                      ···                             304 (51)                                           236 (43)[†](#jah33186-note-0005){ref-type="fn"}
  Sulfamides                      ···                             157 (26)                                           172 (31)
  Other oral hypoglycemic drugs   ···                             172 (29)                                           193 (35)[†](#jah33186-note-0005){ref-type="fn"}

Data are given as number (percentage). ACE indicates angiotensin‐converting enzyme; ARB, angiotensin‐2 receptor blocker; DM, diabetes mellitus; HbA1c, glycosylated hemoglobin.

\**P*\<0.05 vs nondiabetic patients; ^†^ *P*\<0.05 vs diabetic patients with HbA1c \<7%.

###### 

Risk Factor Control at Inclusion, According to Diabetic Status and DM Control

  Variable                          Nondiabetic Patients (n=2887)   Diabetic Patients With HbA1c \<7% (n=594)           Diabetic Patients With HbA1c ≥7% (n=552)
  --------------------------------- ------------------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------
  Current smoker                    343 (12)                        47 (8)[\*](#jah33186-note-0007){ref-type="fn"}      69 (13)[†](#jah33186-note-0007){ref-type="fn"}
  Body mass index, kg/m^2^          27±4                            30±5[\*](#jah33186-note-0007){ref-type="fn"}        31±6[\*](#jah33186-note-0007){ref-type="fn"} ^,^ [†](#jah33186-note-0007){ref-type="fn"}
  Systolic blood pressure, mm Hg    131±15                          135±16[\*](#jah33186-note-0007){ref-type="fn"}      135±16[\*](#jah33186-note-0007){ref-type="fn"}
  Diastolic blood pressure, mm Hg   75±9                            76±9[\*](#jah33186-note-0007){ref-type="fn"}        76±10
  LDL cholesterol, g/L              0.91±0.28                       0.84±0.26[\*](#jah33186-note-0007){ref-type="fn"}   0.84±0.29[\*](#jah33186-note-0007){ref-type="fn"}

Data are given as mean±SD or number (percentage). DM indicates diabetes mellitus; HbA1c, glycosylated hemoglobin; LDL, low‐density lipoprotein.

\**P*\<0.05 vs nondiabetic patients; ^†^ *P*\<0.05 vs diabetic patients with HbA1c \<7%.

A comparison of baseline characteristics, medications, and risk factor control in diabetic patients according to availability of HbA1c is provided in Table [S1](#jah33186-sup-0001){ref-type="supplementary-material"}. Except for a lower proportion of antidiabetic medications in patients without HbA1c available at inclusion, no major differences were observed.

Follow‐Up and Outcomes {#jah33186-sec-0015}
----------------------

A 5‐year clinical follow‐up was achieved in 4094 (98%) of the 4184 patients included in the registry. There were 677 deaths (n=353 noncardiovascular, n=269 cardiovascular, and n=55 unknown cause), 170 MIs, and 96 ischemic strokes. The composite ischemic end point of cardiovascular death, MI, or ischemic stroke occurred in 536 patients. The cumulative rate for the composite ischemic end point was 14% at 5‐year follow‐up (2.8%/year). There were 123 major bleeding events during the 5‐year follow‐up (0.7%/year). In most of the cases, the site of bleeding was gastrointestinal (n=56 \[45.5%\]); there were 35 intracranial bleedings (28.5%).

When compared with nondiabetic patients, the risk of the ischemic end point was higher in diabetic patients with an HbA1c ≥7% (3.9%/year versus 2.6%/year; unadjusted HR, 1.57; 95% CI, 1.25--1.93; *P*\<0.0001) (Table [4](#jah33186-tbl-0004){ref-type="table"}). By contrast, the risk of the ischemic end point of diabetic patients with an HbA1c \<7% was indistinguishable from that of nondiabetic patients (2.8%/year versus 2.6%/year; unadjusted HR, 1.06; 95% CI, 0.83--1.36; *P*=0.623). Similar results were obtained when adjusted for baseline characteristics (age, sex, persistent angina at inclusion, history of hypertension, current smoker, prior MI, multivessel CAD, prior coronary revascularization, prior stroke, atrial fibrillation, and left ventricular ejection fraction \[Table [4](#jah33186-tbl-0004){ref-type="table"}\]); the results were unchanged when the analysis was also adjusted for prior drug‐eluting coronary stent implantation, body mass index, systolic blood pressure, and low‐density lipoprotein cholesterol (Table [S2](#jah33186-sup-0001){ref-type="supplementary-material"}). The unadjusted HR for the ischemic end point of diabetic patients with an HbA1c ≥7% versus diabetic patients with an HbA1c \<7% was 1.47 (95% CI, 1.09--1.98; *P*=0.012). Figure [1](#jah33186-fig-0001){ref-type="fig"} shows unadjusted Kaplan‐Meier curves for the ischemic end point for nondiabetic patients, diabetic patients with an HbA1c \<7%, and diabetic patients with an HbA1c ≥7%. In a sensitivity analysis reclassifying deaths from unknown causes as noncardiovascular deaths, similar results were obtained: the unadjusted HR for diabetic patients with an HbA1c ≥7% (versus nondiabetic patients) was 1.63 (95% CI, 1.29--2.06; *P*\<0.0001), whereas the unadjusted HR for diabetic patients with an HbA1c \<7% (versus nondiabetic patients) was 1.12 (95% CI, 0.86--1.44; *P*=0.407). In another sensitivity analysis (Table [S3](#jah33186-sup-0001){ref-type="supplementary-material"}), we assessed the following separately: (1) all‐cause death and (2) the nondeath composite of MI or ischemic stroke (with death as a competing variable). We found similar results, with diabetic patients with an HbA1c ≥7% having worse outcome than nondiabetic patients, and diabetic patients with an HbA1c \<7% having similar outcome than nondiabetic patients.

###### 

Unadjusted and Adjusted HRs for Clinical Outcome, According to Diabetic Status and DM Control

  Variable                                                                               HR (95% CI)         *P* Value
  -------------------------------------------------------------------------------------- ------------------- -----------
  Composite end point: cardiovascular death, myocardial infarction, or ischemic stroke                       
  Unadjusted                                                                                                 
  Nondiabetic patients                                                                   Reference           ···
  Diabetic patients with HbA1c \<7%                                                      1.06 (0.83--1.36)   0.623
  Diabetic patients with HbA1c ≥7%                                                       1.57 (1.25--1.96)   \<0.0001
  Adjusted[a](#jah33186-note-0009){ref-type="fn"}                                                            
  Nondiabetic patients                                                                   Reference           ···
  Diabetic patients with HbA1c \<7%                                                      1.00 (0.78--1.30)   0.975
  Diabetic patients with HbA1c ≥7%                                                       1.41 (1.11--1.78)   0.004
  BARC ≥3 bleeding                                                                                           
  Unadjusted                                                                                                 
  Nondiabetic patients                                                                   Reference           ···
  Diabetic patients with HbA1c \<7%                                                      1.66 (1.04--2.67)   0.035
  Diabetic patients with HbA1c ≥7%                                                       1.75 (1.07--2.86)   0.025
  Adjusted[a](#jah33186-note-0009){ref-type="fn"}                                                            
  Nondiabetic patients                                                                   Reference           ···
  Diabetic patients with HbA1c \<7%                                                      1.72 (1.06--2.78)   0.029
  Diabetic patients with HbA1c ≥7%                                                       1.75 (1.05--2.91)   0.030

BARC indicates Bleeding Academic Research Consortium; CI, confidence interval; DM, diabetes mellitus; HbA1c, glycosylated hemoglobin; HR, hazard ratio.

Adjusted for age, sex, persistent angina at inclusion, history of hypertension, current smoker, prior myocardial infarction, multivessel coronary artery disease, prior coronary revascularization, prior stroke, atrial fibrillation, and left ventricular ejection fraction.

![Cardiovascular death, myocardial infarction, or ischemic stroke during 5‐year follow‐up, according to diabetic status and diabetes mellitus (DM) control. Unadjusted Kaplan‐Meier curves are shown. HbA1c indicates glycosylated hemoglobin.](JAH3-7-e008354-g001){#jah33186-fig-0001}

Finally, when compared with nondiabetic patients, the risk of major bleeding was significantly higher in diabetic patients; this was observed for diabetic patients with an HbA1c \<7% (0.9%/year versus 0.5%/year; unadjusted HR, 1.66; 95% CI, 1.04--2.67; *P*=0.035) and for diabetic patients with an HbA1c ≥7% (0.9%/year versus 0.5%/year; unadjusted HR, 1.75; 95% CI, 1.07--2.86; *P*=0.025). Similar results were obtained when adjusted for baseline characteristics (Table [4](#jah33186-tbl-0004){ref-type="table"}). No difference in bleeding risk was observed between diabetic patients with an HbA1c ≥7% versus diabetic patients with an HbA1c \<7% (HR, 1.05; 95% CI, 0.58--1.90; *P*=0.869). Figure [2](#jah33186-fig-0002){ref-type="fig"} shows unadjusted Kaplan‐Meier curves for major bleeding for nondiabetic patients, diabetic patients with an HbA1c \<7%, and diabetic patients with an HbA1c ≥7%.

![Bleeding Academic Research Consortium (BARC) ≥3 bleeding during 5‐year follow‐up, according to diabetic status and diabetes mellitus (DM) control. Unadjusted Kaplan‐Meier curves are shown. HbA1c indicates glycosylated hemoglobin.](JAH3-7-e008354-g002){#jah33186-fig-0002}

Discussion {#jah33186-sec-0016}
==========

It is well established that patients with CAD who also have DM are at higher risk of ischemic events than their nondiabetic counterparts. This has been shown in different settings: after MI/acute coronary syndrome (ACS),[1](#jah33186-bib-0001){ref-type="ref"} after percutaneous coronary interventions,[2](#jah33186-bib-0002){ref-type="ref"} and in patients with stable CAD.[3](#jah33186-bib-0003){ref-type="ref"} There has, however, been tremendous progress within recent years on secondary prevention for stable CAD. In addition, physicians taking care of patients with CAD are likely to identify those with DM as higher‐risk individuals and may thus provide more stringent secondary prevention to this subgroup.

The prognosis of diabetic patients with CAD is not uniform. Among indicators that have been the most studied in this subgroup is the level of HbA1c. There are consistent data in the literature indicating a higher risk of cardiovascular events in diabetic patients with CAD with high HbA1c versus low HbA1c. However, this association has been mainly described in cohorts of patients undergoing percutaneous coronary intervention[4](#jah33186-bib-0004){ref-type="ref"}, [5](#jah33186-bib-0005){ref-type="ref"} and less frequently in patients with stable CAD (ie, at a chronological distance from any MI and/or coronary revascularization).[22](#jah33186-bib-0022){ref-type="ref"} More important, poor glucose control per se might not be the primary reason for the worse outcome in diabetic patients with CAD with high HbA1c. Indeed, strategies of intensive glucose control have failed to decrease major cardiovascular events in diabetic patients.[23](#jah33186-bib-0023){ref-type="ref"}, [24](#jah33186-bib-0024){ref-type="ref"} High HbA1c levels may, thus, be linked to other confounders, which are associated with the worse outcome. Diabetic patients with CAD with higher HbA1c may, for example, have more difficulties in treating DM and/or longer duration of DM. No matter what the reason is, a high HbA1c should be considered as a warning sign in diabetic patients with CAD.

Risk stratification is an important part of management for patients with chronic diseases. Our data demonstrate that the association of high HbA1c with more frequent ischemic events when DM coexists with CAD can be extended to patients with very stable CAD. Our results also show that, during a 5‐year follow‐up period, ischemic event rates in diabetic patients with HbA1c \<7% are almost identical to reference rates in nondiabetic patients. It should be underscored that these findings remain unchanged after adjusting for baseline characteristics. This is important because diabetic patients may have different risk features and/or may have undergone different procedures, such as more frequent use of drug‐eluting coronary stent (likely related to the expectation of a higher risk of restenosis[2](#jah33186-bib-0002){ref-type="ref"}).

These results should be interpreted in the context of a high use of secondary prevention medications. Indeed, the prescription rates of antiplatelets, statins, and angiotensin‐converting enzyme inhibitors/angiotensin‐2 receptor blockers in diabetic patients with CAD included in our registry are close to the rates achieved after 1 year in diabetic patients with CAD included in recent clinical trials in which optimal medical therapy was prescribed to all patients.[25](#jah33186-bib-0025){ref-type="ref"} Effective risk factor control (low‐density lipoprotein cholesterol, systolic blood pressure, and smoking cessation) in our cohort was also similar to what was obtained in these clinical trials in which prespecified targets were defined.[25](#jah33186-bib-0025){ref-type="ref"}

Although the recurrence of ischemic events is a major issue in patients with CAD, recent data have shown that the risk of bleeding events should also be taken into account, especially in a context of modern secondary prevention with a wide use of potent antithrombotic treatments.[6](#jah33186-bib-0006){ref-type="ref"}, [7](#jah33186-bib-0007){ref-type="ref"} As a consequence, risk scores have been developed in patients with CAD to predict risks for ischemic and bleeding events and, therefore, to guide clinical decisions about intensity and duration of antithrombotic therapy.[12](#jah33186-bib-0012){ref-type="ref"}, [26](#jah33186-bib-0026){ref-type="ref"}, [27](#jah33186-bib-0027){ref-type="ref"} The role of DM as a risk factor for bleeding has been well established in patients with ACS.[12](#jah33186-bib-0012){ref-type="ref"} However, in this unstable setting, DM is rather more identified as a risk factor of ischemic events than as a risk factor of bleeding in the physician\'s mind. Indeed, DM has been associated with a better benefit/risk ratio of more potent P2Y~12~‐ADP receptor antagonists (versus clopidogrel) in ACS.[13](#jah33186-bib-0013){ref-type="ref"}, [28](#jah33186-bib-0028){ref-type="ref"} In the past, DM was also a criterion to prescribe upstream glycoprotein IIb to IIIa inhibitors in the context of high‐risk non--ST‐segment--elevation ACS.[29](#jah33186-bib-0029){ref-type="ref"} These results, therefore, suggest that we should be more aggressive on antithrombotics in patients with DM, despite their overall higher risk of bleeding compared with nondiabetic patients. Recently, these results obtained in ACS look to have been extended to the stable CAD situation. Indeed, DM was a targeted variable to enrich the population of the PEGASUS (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin) and COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trials to select higher‐risk patients for more aggressive antithrombotic therapy regimens.[30](#jah33186-bib-0030){ref-type="ref"}, [31](#jah33186-bib-0031){ref-type="ref"} The relation between DM and bleeding in patients with stable CAD is, however, less clear, and the impact of the HbA1c level is unknown in this context. In selected patients with stabilized CAD included in the randomized DAPT (Dual Antiplatelet Therapy) study, DM was not associated with an increased bleeding risk.[26](#jah33186-bib-0026){ref-type="ref"} By contrast, DM was associated with a higher risk of bleeding in the REACH (Reduction of Atherothrombosis for Continued Health) Registry, which included stable patients with or at risk of atherosclerosis and mainly patients with CAD.[32](#jah33186-bib-0032){ref-type="ref"} Our data, obtained in patients widely treated by antithrombotic treatments, show that the risk of major (Bleeding Academic Research Consortium ≥3) bleeding is significantly higher in diabetic than in nondiabetic patients and are concordant with the results observed in the REACH Registry. At variance to what we observed for ischemic end points, the increase in risk was not solely observed in diabetic patients with an HbA1c ≥7% but also in diabetic patients with an HbA1c \<7%. Our results, therefore, suggest that the HbA1c level may help physicians to manage antithrombotic therapies in patients with stable CAD and that more aggressive antithrombotic regimen should be reserved to patients with DM with an HbA1c ≥7% who seem to have the best benefit/risk ratio in our analysis.

Study Limitations {#jah33186-sec-0017}
-----------------

First, our data reflect the practice in a regional area, and it will have to be determined whether these findings are representative of practices in other parts of the world. In France, social coverage and health insurance are uniform over the whole territory, and stable CAD is one of the conditions entitled to full reimbursement of all costs, including medications and diagnostic and therapeutic procedures. Second, the fact that the inclusion was done by cardiologists may overestimate the extent to which these patients are managed in relation to guidelines, and the reality of secondary prevention may be worse. It must also be underscored that the CORONOR population includes individuals with or without prior events and, therefore, the events ascertained in follow‐up in this study include incident and recurrent events. Third, HbA1c levels were available only at inclusion in the registry, and the HbA1c level at inclusion may not correspond to a stable HbA1c in subsequent years. The choice of a cutoff of 7% for HbA1c could be debated. As previously stated, this value was derived from international recommendations for the management of DM in stable CAD.[7](#jah33186-bib-0007){ref-type="ref"} Fourth, to achieve sufficient statistical power, we focused the analysis on a composite ischemic end point (cardiovascular death, MI, or stroke). This combination of events has, however, been extensively used as the primary end point of multiple large randomized controlled trials performed in patients with stable CAD and in patients with DM, including major recent trials.[30](#jah33186-bib-0030){ref-type="ref"}, [31](#jah33186-bib-0031){ref-type="ref"}, [33](#jah33186-bib-0033){ref-type="ref"} Finally, the number of major bleeding events was relatively limited.

In conclusion, our data demonstrate that patients with stable CAD who also have DM achieve a high level of secondary prevention. In this context, the 5‐year cardiovascular outcome of diabetic patients with CAD with an HbA1c \<7% was similar to that of nondiabetic patients with CAD. By contrast, the increase in bleeding risk associated with DM was observed in patients with HbA1c \<7% and in patients with HbA1c ≥7%. The level of HbA1c should be taken into account for future research and intervention trials in diabetic patients with CAD and may help physicians to manage prolonged antithrombotic therapies in this high‐risk subgroup.
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